IBM, University of Alberta develop AI capable of predicting schizophrenia

Researchers at IBM and the University of Alberta have developed artificial intelligence (AI) algorithms capable of predicting schizophrenia with 74 percent accuracy.

Published in Schizophrenia, a study outlined how the tool aims to be a starting point for scientists in identifying neurological biomarkers for predicting schizophrenia and its severity. Researchers analyzed brain MRI data from patients with schizophrenia and schizoaffective disorders, as well as healthy patients, to train the AI to identify schizophrenic behavior.

“This unique, innovative multidisciplinary approach opens new insights and advances our understanding of the neurobiology of schizophrenia, which may help to improve the treatment and management of the disease,” said Serdar Dursun, MD, PhD, professor of psychiatry and neuroscience at the University of Alberta. “We’ve discovered a number of significant abnormal connections in the brain that can be explored in future studies, and AI-created models bring us one step closer to finding objective neuroimaging-based patterns that are diagnostic and prognostic markers of schizophrenia.”

The tool examined 95 scans from participants to develop models of schizophrenia to identify connections in the brain associated with the chronic disease. Results showed the AI algorithm could tell the difference between patients with schizophrenia and control individuals with a 74 percent rate of accuracy. The AI could also determine the severity of symptoms

“The ultimate goal of this research effort is to identify and develop objective, data-driven measures for characterizing mental states, and apply them to psychiatric and neurological disorders” said Ajay Royyuru, vice president of healthcare and life sciences with IBM Research. “We also hope to offer new insights into how AI and machine learning can be used to analyze psychiatric and neurological disorders to aid psychiatrists in their assessment and treatment of patients.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.